您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > BIM 23042
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
BIM 23042
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
BIM 23042图片
CAS NO:111857-96-6
包装:1mg
规格:98%
市场价:2223元
分子量:1180.44

产品介绍
Antagonist of neuromedin B receptor,selective
CAS:111857-96-6
分子式:C62H73N11O9S2
分子量:1180.44
纯度:98%
存储:Store at -20°C

Background:

Ki: 49 ±14 nM for neuromedin B-induced endpoint in huNMBR cells


Neuromedin B, a mammalian peptide of the bombesinlike peptide family sharing amino acid homology with its amphibian counterpart ranatensin, elicits a diverse array of biological responses in central and peripheral tissues. BIM 23042 [D-Nal-Cys-Tyr- D-Trp-Lys-Val-Cys-Nal-NH2] is a selective neuromedin B antagonist.


In vitro: BIM 23042 has a l00-fold greater affinity for BB1 receptors than BB2 receptors. The submaximal mobilisation observed with neuromedin B (1 nM) was abolished by BIM 23042 but restored with a subsequently higher concentration of neuromedin B (1 μM). BIM 23042 competitively inhibited neuromedin B-induced endpoint in huNMBR cells with a Ki of 49 ±14 nM [1].


In vivo: In cat upper GI tract, SSocta, at concentrations of 10 mM, did not influence the smooth muscle tone but shifted NMB concentration response to the right yielding (Ki=1.7±0.8 mM). Ssocta inhibited both NMB- and GRP-induced contractions on the esophagus. the NMB-receptor antagonist SSocta had no effect on circular fundic muscle indicating the absence of this receptor subtype on fundus. [2].


Clinical trial: Up to now, BIM 23042 is still in the preclinical development stage.


参考文献:
[1] Ryan RR, Taylor JE, Daniel JL, Cowan A.  Pharmacological profiles of two bombesin analogues in cells transfected with human neuromedin B receptors. Eur J Pharmacol. 1996 Jun 13;306(1-3):307-14.
[2] Milusheva EA,?Kortezova NI,?Mizhorkova ZN,?Papasova M,?Coy DH,?Bálint A,?Vizi ES,?Varga G.  Role of different bombesin receptor subtypes mediating contractile activity in cat upper gastrointestinal tract. Peptides.?1998;19(3):549-56.